Science & Enterprise subscription

Follow us on Twitter

  • A biotechnology start-up enterprise plans to produce milk directly from mammary cells in the lab without crops, ani… https://t.co/yoFjMlCFuM
    about 2 hours ago
  • New post on Science and Enterprise: New Company Developing Cell-Based Milk https://t.co/0mW5Nbpe1L #Science #Business
    about 2 hours ago
  • Microsoft Corp. plans to invest $1 billion over the next four years to create technologies for removing carbon from… https://t.co/1GXEhclsNr
    about 6 hours ago
  • New post on Science and Enterprise: Microsoft Launches $1 Billion Climate Fund https://t.co/vior71EwQD #Science #Business
    about 6 hours ago
  • A chart posted on Friday by Statista provides yet another sign our planet is getting dangerously warmer.… https://t.co/1B0EREH07R
    about 1 day ago

Please share Science & Enterprise

CE Mark Approved for Migraine Implant Therapy

PNS illustration (St. Jude Medical)

PNS illustration (St. Jude Medical)

St. Jude Medical in St. Paul, Minnesota says it received the European CE Mark approval for its implanted neurostimulation device for patients with chronic migraines. The CE marking (an acronym for the French “Conformite Europeenne”) certifies that a product has met EU health, safety, and environmental requirements for consumer safety.

The company’s Genesis system for peripheral nerve stimulation (PNS) of the occipital nerves is designed for the management of the pain and disability associated with intractable chronic migraine. This type of migraine is defined as headache lasting at least four hours per day for 15 or more days per month, causing at least moderate disability, and not responding to three or more preventive drugs.

PNS therapy (illustrated at right) for this condition involves the delivery of mild electrical pulses to the occipital nerves that are located just beneath the skin at the back of the head. A small electrical lead or leads are placed under the skin and connected to the neurostimulator which produces the pulses of stimulation.

St. Jude says the CE Mark approval was based on the results of a randomized, double-blind, controlled clinical trial that collected data from 157 patients. Patients enrolled in the study suffered from headache, on average, 26 days per month.

The findings indicate that at 12 weeks, participants in the active group had 41 percent lower overall disability compared to a 13 percent reduction in the control group, based on the Migraine Disability Assessment (MIDAS) questionnaire. Also at 12 weeks, patients who received stimulation had 36 percent fewer headache days compared to the control group which reported a 25 percent decrease.

Of the patients who used the PNS device for a year, about two-thirds  (65 to 68 percent) each reported excellent or good pain relief, said that their quality of life had improved, and were satisfied or very satisfied with the results of their procedure.

Read More: Study Explains How Tinted Lenses Offer Relief from Migraines

*     *     *

Please share Science & Enterprise ...
error

2 comments to CE Mark Approved for Migraine Implant Therapy